Behavioural sensitization of mesolimbic dopamine D-2 receptors in chronic fluoxetine-treated rats

被引:49
作者
Collu, M [1 ]
Poggiu, AS [1 ]
Devoto, P [1 ]
Serra, G [1 ]
机构
[1] UNIV SASSARI,DEPT PHARMACOL SCI,I-07100 SASSARI,ITALY
关键词
dopamine receptor; mesolimbic dopamine system; antidepressant drug; fluoxetine; chronic treatment;
D O I
10.1016/S0014-2999(97)00006-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A common action of chronic antidepressant treatments is the potentiation of dopaminergic transmission in the limbic system. We now report that chronic, but not acute, treatment with fluoxetine (2.5 mg/kg by intragastric gavage once a day for 21 days) potentiates the locomotor stimulant effect of quinpirole, a selective dopamine D-2/D-3 receptor agonist. However, neither quinpirole-induced stereotypies nor the sedative effects elicited by low doses of this dopamine receptor agonist are influenced by chronic fluoxetine. These results suggest that fluoxetine, as well as classical antidepressants, sensitize postsynaptic dopamine D-2/D-3 receptors in the mesolimbic system. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:123 / 127
页数:5
相关论文
共 21 条
  • [1] ARNT J, 1984, POL J PHARMACOL PHAR, V36, P221
  • [2] ASHBY CR, 1995, P SOC NEUROSCI, V21
  • [3] CLINICAL AND BIOCHEMICAL ASPECTS OF DEPRESSIVE-DISORDERS .2. TRANSMITTER RECEPTOR THEORIES
    CALDECOTTHAZARD, S
    MORGAN, DG
    DELEONJONES, F
    OVERSTREET, DH
    JANOWSKY, D
    [J]. SYNAPSE, 1991, 9 (04) : 251 - 301
  • [4] Collu M, 1994, POL J PHARMACOL, V46, P315
  • [5] Collu M, 1996, BEHAV PHARMACOL, V7, P18
  • [6] PHARMACOLOGICAL AND ANATOMICAL SUBSTRATES OF AMPHETAMINE RESPONSE IN RAT
    CREESE, I
    IVERSEN, SD
    [J]. BRAIN RESEARCH, 1975, 83 (03) : 419 - 436
  • [7] ANTIDEPRESSANT-LIKE EFFECT OF SELECTIVE DOPAMINE D-1 RECEPTOR AGONISTS IN THE BEHAVIORAL DESPAIR ANIMAL-MODEL OF DEPRESSION
    DAQUILA, PS
    COLLU, M
    PANI, L
    GESSA, GL
    SERRA, G
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 262 (1-2) : 107 - 111
  • [8] DEMONTIS G, 1989, EUR J PHARMACOL, V180, P31
  • [9] Fibiger H., 1993, SEMIN NEUROSCI, V5, P321, DOI 10.1016/S1044-5765(05)80039-9
  • [10] GAMBARANA C, 1995, BEHAV PHARMACOL, V6, P66